2021
DOI: 10.1016/j.jmst.2020.08.031
|View full text |Cite
|
Sign up to set email alerts
|

Possibilities and impossibilities of magnetic nanoparticle use in the control of infectious biofilms

Abstract: Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
12
0
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
3

Relationship

3
7

Authors

Journals

citations
Cited by 24 publications
(13 citation statements)
references
References 75 publications
0
12
0
1
Order By: Relevance
“…Nanotechnology is increasingly being developed as one of the novel strategies in the field of biomedicine. Nanomaterials have unique advantages in antibacterial applications over other materials owing to their ultra-small size, large surface area-to-mass ratio, high reactivity, and enriched multifunction integration. Particularly, magnetic nanoparticles (MNPs), approved by the U.S. Food and Drug Administration (FDA), have achieved great prominence in the antimicrobial therapy owing to their small size and high magnetism, immunoregulatory activity, feasible large-scale production, cell membrane penetrability, biocompatibility, and flexible surface functionalization. For instance, MNPs have been used to combat the bacterial infections, such as Escherichia coli, Staphylococcus aureus [specifically Methicillin-resistant Staphylococcus Aureus (MRSA)], Salmonella enteritidis, and so forth, which have been applied to wound, blood, skin, and orthopedic and liver diseases. However, MNPs were not effective in removing biofilms. , …”
Section: Introductionmentioning
confidence: 99%
“…Nanotechnology is increasingly being developed as one of the novel strategies in the field of biomedicine. Nanomaterials have unique advantages in antibacterial applications over other materials owing to their ultra-small size, large surface area-to-mass ratio, high reactivity, and enriched multifunction integration. Particularly, magnetic nanoparticles (MNPs), approved by the U.S. Food and Drug Administration (FDA), have achieved great prominence in the antimicrobial therapy owing to their small size and high magnetism, immunoregulatory activity, feasible large-scale production, cell membrane penetrability, biocompatibility, and flexible surface functionalization. For instance, MNPs have been used to combat the bacterial infections, such as Escherichia coli, Staphylococcus aureus [specifically Methicillin-resistant Staphylococcus Aureus (MRSA)], Salmonella enteritidis, and so forth, which have been applied to wound, blood, skin, and orthopedic and liver diseases. However, MNPs were not effective in removing biofilms. , …”
Section: Introductionmentioning
confidence: 99%
“…Targeting NIR irradiation to an infection site requires extremely precise dosing of photothermal nanoparticles to prevent collateral tissue damage [13] as the heat generated spreads through adjacent tissue. Magnetic targeting of photothermal nanoparticles to an infection site has also been suggested [27][28][29], but the current state of clinically applied magnetic targeting instrumentation impedes targeting to micron-sized infectious biofilms [30].…”
Section: Discussionmentioning
confidence: 99%
“…This finding indicates that magnetic targeting is a promising strategy for the treatment of drug‐resistant biofilm infections. However, in vivo magnetic targeting relies on sophisticated techniques, and the current magnetic‐targeting techniques are insufficient to precisely target microscale infectious biofilms, and the clinical translation of the use of MNPs is still difficult (Quan, Zhang, et al, 2021).…”
Section: Advantages Of Nanocarriers For Combating Biofilmsmentioning
confidence: 99%